HilleVax announced that it has received $135 million in an oversubscribed crossover round of funding led by Frazier Management, L.L.C. on September 8, 2021. The transaction included participation from RA Capital Management, L.P., Deerfield Management Company, L.P., Abingworth LLP, Lightspeed Ventures, LLC, Perceptive Advisors LLC, Franklin Resources, Inc., Catalys Pacific, Samsara BioCapital LLC, BVF Partners, L.P., Qiming Venture Partners USA, Greenspring Associates, Inc., Richard King Mellon Foundation and Sahsen Ventures LLC. As part of the transaction, Patrick Heron of Frazier Management, L.L.C., Elise Wang of Deerfield Management Company, L.P., Shelley Chu of Lightspeed Ventures, LLC,Julie Gerberding of of Merck, Jeri Hilleman of Omada Health, Jaime Sepulveda of of the University of California San Francisco (UCSF) Institute for Global Health Sciences, Susan Silbermann of of Emerging Markets at Pfizer and Global President of Pfizer Vaccines and Rajeev Venkayya of of the Global Vaccine Business Unit at Takeda have joined the company's board of directors.